Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-09T09:28:07.418Z Has data issue: false hasContentIssue false
  • English
  • Français

Rapid development of pulmonary hypertension during treatment of paediatric cancer

Published online by Cambridge University Press:  25 January 2019

Manish Aggarwal ,
Laura Schuettpelz ,
Julie Kolodziej  and
R. Mark Grady
Manish Aggarwal*
Affiliation:
Department of Pediatrics, Washington University School of Medicine, Children’s Place, St Louis, MO, USA
Laura Schuettpelz
Affiliation:
Department of Pediatrics, Washington University School of Medicine, Children’s Place, St Louis, MO, USA
Julie Kolodziej
Affiliation:
Department of Pediatrics, Washington University School of Medicine, Children’s Place, St Louis, MO, USA
R. Mark Grady
Affiliation:
Department of Pediatrics, Washington University School of Medicine, Children’s Place, St Louis, MO, USA
*
Author for correspondence: M. Aggarwal, Texas Children’s Hospital/Baylor College of Medicine, Pediatric Cardiology, 6621 Fannin Street, MC 19345-C, Houston, TX 77030, USA. Tel: 832-826-5715; Fax: 832-825-1906; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Paediatric pulmonary hypertension has been described as a secondary complication of multiple diseases and their treatment. Limited information exists about the relationship between pulmonary hypertension and cancer in children. A review of charts was performed in all patients treated for cancer and developed pulmonary hypertension. A total of four patients developed pulmonary hypertension during treatment of cancer. All patients had solid tumors, had echocardiographic evidence of elevated right ventricular pressures, and required intensive care stays. Treatment courses included inhaled and oral pulmonary vasodilators along with systemic steroids. Each had normalisation of echocardiograms and resolution of pulmonary symptoms. Prompt diagnosis of pulmonary hypertension and treatment with pulmonary vasodilators and steroids are considered important measures followed by chemotherapy and radiation regimens.

Keywords

Secondary pulmonary hypertensionpaediatric pulmonary hypertensionsolid tumour treatmentintensive care
Type
Original Article
Information
Cardiology in the Young , Volume 29 , Issue 3 , March 2019 , pp. 286 - 289
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Cite this article: Aggarwal M, Schuettpelz L, Kolodziej J, Grady RM (2019) Rapid development of pulmonary hypertension during treatment of paediatric cancer. Cardiology in the Young29: 286–289. doi: 10.1017/S1047951118002196

References

1. Abman, SH, Hansmann, G, Archer, SL, et al. Pediatric pulmonary hypertension. Circulation 2015; 132: 2037–2099.Google Scholar
2. Mourani, PM, Sontag, MK, Younoszai, A, et al. Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015; 191: 87–95.Google Scholar
3. Kozlik-Feldmann, R, Hansmann, G, Bonnet, D, Schranz, D, Apitz, C, Michel-Behnke, I. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network. Heart Br Card Soc 2016; 102: ii42–ii48.Google Scholar
4. Zuckerman, WA, Rosenzweig, EB. Pulmonary hypertension in children with sickle cell disease. Expert Rev Respir Med 2011; 5: 233–243.Google Scholar
5. Hutson, S, Baerg, J, Deming, D, St Peter, SD, Hopper, A, Goff, DA. High prevalence of pulmonary hypertension complicates the care of infants with omphalocele. Neonatology 2017; 112: 281–286.Google Scholar
6. Versluys, AB, Bresters, D. Pulmonary complications of childhood cancer treatment. Paediatr Respir Rev 2016; 17: 63–70.Google Scholar
7. Ranchoux, B, Günther, S, Quarck, R, et al. Chemotherapy-induced pulmonary hypertension. Am J Pathol 2015; 185: 356–371.Google Scholar
8. Ballout, FA, Manshad, AS, Okwuosa, TM. Pulmonary hypertension and cancer: etiology, diagnosis, and management. Curr Treat Options Cardiovasc Med 2017: 19.Google Scholar
9. Montani, D, Bergot, E, Günther, S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128–2137.Google Scholar
10. Al-Ghanem, G, Shah, P, Thomas, S, Banfield, L, El Helou, S, Fusch, C, Mukerji, A. Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. J Perinatol Off J Calif Perinat Assoc 2017; 37: 414–419.Google Scholar
11. Jodele, S, Hirsch, R, Laskin, B, Davies, S, Witte, D, Chima, R. Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2013; 19: 202–207.Google Scholar
12. Price, LC, Wort, SJ, Perros, F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141: 210–221.Google Scholar
13. Wang, W, Wang, YL, Chen, XY, Li, YT, Hao, W, Jin, YP, Han, B. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep 2011; 5.Google Scholar
14. Price, LC, Montani, D, Tcherakian, C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 2011; 37: 813–822.Google Scholar
15. Ogawa, A, Nakamura, K, Mizoguchi, H, et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2011; 183: 139–140.Google Scholar
16. Aggarwal, M, Grady, RM. Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication. Cardiol Young 2017; 27: 1410–1412.Google Scholar